Redeemer's University, Ede, Osun State, Nigeria.
Infectious Diseases and Environmental Health Research Group (IDEHRG), Department of Microbiology, University of Ilorin, Ilorin, Kwara State, Nigeria.
Curr Opin Immunol. 2021 Aug;71:27-33. doi: 10.1016/j.coi.2021.03.008. Epub 2021 Apr 17.
Ebola Virus Disease (EVD) is an emerging zoonotic disease with intermittent outbreaks in Central and West African countries. The unpredictable high case fatality rate has made it a disease of public health concern. Different vaccine platforms have shown prophylactic protection in human and non-human primates, with the progress towards a licensed vaccine greatly accelerated in response to the devastating outbreak of EVD in West Africa from 2013-2016. Currently, two vaccines: Ervebo (rVSV-ZEBOV) and a two-dose combination of Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo) have been licensed and in use. The licensing of an Ebola vaccine for use is challenging for several reasons, including the sporadic and limited nature of EVD outbreaks and the enormous resources needed to bring a vaccine to licensure. While vaccine solutions remain important in reducing the fatality of EVD, other strategic interventions are necessary for the prevention and control of EVD.
埃博拉病毒病（EVD）是一种新兴的人畜共患病，间歇性在中非和西非国家爆发。不可预测的高病死率使其成为公共卫生关注的疾病。不同的疫苗平台在人类和非人类灵长类动物中显示出预防保护作用，为应对 2013-2016 年西非埃博拉疫情的破坏性爆发，疫苗的研发进展大大加快。目前，已有两种疫苗获得许可并投入使用：Ervebo（rVSV-ZEBOV）和两剂组合的 Zabdeno（Ad26.ZEBOV）和 Mvabea（MVA-BN-Filo）。出于多种原因，埃博拉疫苗的许可使用具有挑战性，包括埃博拉疫情的零星和有限性质，以及将疫苗推向许可所需的巨大资源。虽然疫苗解决方案仍然是降低埃博拉病死率的重要手段，但还需要其他战略干预措施来预防和控制埃博拉。
